Daraxonrasib

Pharmaceutical compound

Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma (PDAC) containing KRAS G12X mutations. It received a breakthrough therapy designation from the US FDA in 2025.

Also known as...RMC-6236
Pancreatic Cancer Pill Doubles Survival

Pancreatic Cancer Pill Doubles Survival An experimental pill has doubled survival time for advanced pancreatic cancer patients.